These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 36251540)
1. Aberrant p53 expression is associated with neoplastic progression in Barrett oesophagus diagnosed as indefinite for dysplasia. Chen X; Liu BL; Harpaz N; Zhu H; Polydorides AD; Liu Q Histopathology; 2023 Feb; 82(3):454-465. PubMed ID: 36251540 [TBL] [Abstract][Full Text] [Related]
2. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia. Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445 [TBL] [Abstract][Full Text] [Related]
3. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia. Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470 [TBL] [Abstract][Full Text] [Related]
4. The utility of P53 immunohistochemistry in the diagnosis of Barrett's oesophagus with indefinite for dysplasia. Januszewicz W; Pilonis ND; Sawas T; Phillips R; O'Donovan M; Miremadi A; Malhotra S; Tripathi M; Blasko A; Katzka DA; Fitzgerald RC; di Pietro M Histopathology; 2022 Jun; 80(7):1081-1090. PubMed ID: 35274753 [TBL] [Abstract][Full Text] [Related]
5. The significance of "indefinite for dysplasia" grading in Barrett metaplasia. Younes M; Lauwers GY; Ertan A; Ergun G; Verm R; Bridges M; Woods K; Meriano F; Schmulen C; Johnson C; Barroso A; Schwartz J; McKechnie J; Lechago J Arch Pathol Lab Med; 2011 Apr; 135(4):430-2. PubMed ID: 21466357 [TBL] [Abstract][Full Text] [Related]
6. Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Duits LC; Phoa KN; Curvers WL; Ten Kate FJ; Meijer GA; Seldenrijk CA; Offerhaus GJ; Visser M; Meijer SL; Krishnadath KK; Tijssen JG; Mallant-Hent RC; Bergman JJ Gut; 2015 May; 64(5):700-6. PubMed ID: 25034523 [TBL] [Abstract][Full Text] [Related]
7. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study. Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571 [TBL] [Abstract][Full Text] [Related]
8. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study. Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963 [TBL] [Abstract][Full Text] [Related]
9. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Montgomery E; Goldblum JR; Greenson JK; Haber MM; Lamps LW; Lauwers GY; Lazenby AJ; Lewin DN; Robert ME; Washington K; Zahurak ML; Hart J Hum Pathol; 2001 Apr; 32(4):379-88. PubMed ID: 11331954 [TBL] [Abstract][Full Text] [Related]
10. Persistent indefinite for dysplasia in Barrett's esophagus is a risk factor for dysplastic progression to low-grade dysplasia. Henn AJ; Song KY; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ Dis Esophagus; 2020 Sep; 33(9):. PubMed ID: 32399569 [TBL] [Abstract][Full Text] [Related]
11. Use of p53 immunohistochemistry in conjunction with routine histology improves risk stratification of patients with Barrett's oesophagus during routine clinical care. Tokuyama M; Geisler D; Deitrick C; Fasanella KE; Chennat JS; McGrath KM; Pai RK; Davison JM Histopathology; 2020 Sep; 77(3):481-491. PubMed ID: 32431062 [TBL] [Abstract][Full Text] [Related]
12. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia. Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917 [TBL] [Abstract][Full Text] [Related]
13. Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort. Song KY; Henn AJ; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ Dis Esophagus; 2020 Mar; 33(2):. PubMed ID: 31274147 [TBL] [Abstract][Full Text] [Related]
14. Progression from low-grade dysplasia to malignancy in patients with Barrett's esophagus diagnosed by two or more pathologists. Moole H; Patel J; Ahmed Z; Duvvuri A; Vennelaganti S; Moole V; Dharmapuri S; Boddireddy R; Yedama P; Bondalapati N; Uppu A; Vennelaganti P; Puli S World J Gastroenterol; 2016 Oct; 22(39):8831-8843. PubMed ID: 27818599 [TBL] [Abstract][Full Text] [Related]
15. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ; Gut; 2013 Dec; 62(12):1676-83. PubMed ID: 23256952 [TBL] [Abstract][Full Text] [Related]
16. A Consensus Diagnosis Utilizing Surface KI-67 Expression as an Ancillary Marker in Low-Grade Dysplasia Helps Identify Patients at High Risk of Progression to High-Grade Dysplasia and Esophaegal Adenocarcinoma. Lee C; Hayat U; Song K; Gravely AA; Mesa H; Peltola J; Iwamoto C; Manivel C; Bilal M; Shaheen N; Shaukat A; Hanson BJ Dis Esophagus; 2023 Feb; 36(3):. PubMed ID: 36190180 [TBL] [Abstract][Full Text] [Related]
17. Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma. Solanky D; Krishnamoorthi R; Crews N; Johnson M; Wang K; Wolfsen H; Fleischer D; Ramirez FC; Katzka D; Buttar N; Iyer PG J Clin Gastroenterol; 2019; 53(5):361-365. PubMed ID: 29608452 [TBL] [Abstract][Full Text] [Related]
18. Real-world upper endoscopy utilization patterns among patients with gastroesophageal reflux disease, Barrett esophagus, and Barrett esophagus-related esophageal neoplasia in the United States. Sharma P; Falk GW; Bhor M; Ozbay AB; Latremouille-Viau D; Guérin A; Shi S; Elvekrog MM; Limburg P Medicine (Baltimore); 2023 Mar; 102(12):e33072. PubMed ID: 36961193 [TBL] [Abstract][Full Text] [Related]
19. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia. Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849 [TBL] [Abstract][Full Text] [Related]
20. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Skacel M; Petras RE; Gramlich TL; Sigel JE; Richter JE; Goldblum JR Am J Gastroenterol; 2000 Dec; 95(12):3383-7. PubMed ID: 11151865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]